391 related articles for article (PubMed ID: 22122775)
1. Chemoprevention in familial adenomatous polyposis.
Kim B; Giardiello FM
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
4. Regression of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A Case With a 2-Year Follow-up Without a Prophylactic Colectomy.
Kim KY; Jeon SW; Park JG; Yu CH; Jang SY; Lee JK; Hwang HY
Ann Coloproctol; 2014 Aug; 30(4):201-4. PubMed ID: 25210691
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK; Mehta NA; Singh H; El-Matary W; Bernstein CN
Fam Cancer; 2023 Oct; 22(4):413-422. PubMed ID: 37119510
[TBL] [Abstract][Full Text] [Related]
6. [Rectal carcinoma in a patient with familial adenomatous polyposis coli after colectomy with ileorectal anastomosis and consecutive chemoprevention with sulindac suppositories].
Utech M; Brüwer M; Buerger H; Tübergen D; Senninger N
Chirurg; 2002 Aug; 73(8):855-8. PubMed ID: 12425165
[TBL] [Abstract][Full Text] [Related]
7. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
9. Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.
Aelvoet AS; Buttitta F; Ricciardiello L; Dekker E
Best Pract Res Clin Gastroenterol; 2022; 58-59():101793. PubMed ID: 35988966
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Thun MJ; Henley SJ; Patrono C
J Natl Cancer Inst; 2002 Feb; 94(4):252-66. PubMed ID: 11854387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
12. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
13. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC.
Lynch PM
Digestion; 2007; 76(1):68-76. PubMed ID: 17947820
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
15. Sulindac therapy for familial adenomatous polyposis after colectomy and ileorectal anastomosis.
Mäkelä JT; Laitinen S
Ann Chir Gynaecol; 1994; 83(3):265-7. PubMed ID: 7857074
[TBL] [Abstract][Full Text] [Related]
16. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
[TBL] [Abstract][Full Text] [Related]
17. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of familial adenomatous polyposis.
Lynch PM
Fam Cancer; 2016 Jul; 15(3):467-75. PubMed ID: 27083160
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of carcinogenesis in familial tumors.
Ishikawa H
Int J Clin Oncol; 2004 Aug; 9(4):299-303. PubMed ID: 15375706
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Keller JJ; Giardiello FM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S140-9. PubMed ID: 14508092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
